Liaoning Chengda Biotechnology Co

Liaoning Chengda Biotechnology Co Interest Coverage

The Interest Coverage Ratio of Liaoning Chengda Biotechnology Co (688739.SS) as of Oct 16, 2026 is 12.48. In the previous year, Interest Coverage Ratio was 5.59 — a change of 123.15% (higher).

Interest Coverage

12.48

YoY

123.15%

Last updated:

Interest Coverage Ratio of Liaoning Chengda Biotechnology Co is 2024 12.48 . Interest Coverage Ratio of Liaoning Chengda Biotechnology Co was 2023 5.59 . It decreases by 123.15% higher compared to the previous year.

The Liaoning Chengda Biotechnology Co Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
13.56 CNY
Jan 1, 2019
14.83 CNY
Jan 1, 2020
10.66 CNY
Jan 1, 2021
56.16 CNY
Jan 1, 2022
9.07 CNY
Jan 1, 2023
5.59 CNY
Jan 1, 2024
12.48 CNY
The Liaoning Chengda Biotechnology Co Interest Coverage history
YEARInterest CoverageYoY
12.48+123.15%
5.59-38.31%
9.07-83.85%
56.16+427.00%
10.66-28.13%
14.83+9.38%
13.56—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Liaoning Chengda Biotechnology Co Stock analysis

What does Liaoning Chengda Biotechnology Co do? Liaoning Chengda Biotechnology Co., Ltd. is a prominent entity in the health care sector, specifically operating within the biotechnology industry. Headquartered in Shenyang, located in the Liaoning province of China, the company has established itself as a significant player in the development and commercialization of medical solutions. As of the latest available data, the organization employs a workforce of 1,663 full-time employees, reflecting its substantial operational scale and commitment to research and development activities. The company's primary business focus revolves around the research, development, manufacturing, and sale of vaccines, addressing critical public health needs through innovative biological products. The firm's product portfolio is centered on essential immunizations, including the rabies vaccine for human use and the freeze-dried rabies vaccine for human use. Additionally, the company produces vaccines targeting Japanese encephalitis, specifically offering the inactivated Japanese encephalitis vaccine for human use and the freeze-dried encephalitis inactivated vaccine. These products are marketed under two distinct brand names: Chengda Suda and Chengda Libao, which serve to differentiate the various offerings within the company's lineup. The strategic emphasis on these specific vaccines highlights the company's dedication to combating infectious diseases that pose significant risks to human health. Liaoning Chengda Biotechnology Co., Ltd. entered the public markets through an initial public offering on October 28, 2021, marking a significant milestone in its corporate history and providing it with greater access to capital for future growth and expansion. The company's official online presence can be found at http://www.cdbio.cn, where stakeholders and interested parties can access further information regarding its operations and developments. With its strong foundation in Shenyang and a dedicated team of professionals, the company continues to contribute to the global health care landscape by delivering high-quality vaccine solutions. The combination of its extensive employee base, specialized product range, and public market listing underscores its role as a key contributor to the biotechnology sector in China and beyond. Liaoning Chengda Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Liaoning Chengda Biotechnology Co stock

Interest Coverage Ratio of Liaoning Chengda Biotechnology Co is 12.48 in 2024.

Interest Coverage Ratio of Liaoning Chengda Biotechnology Co changed from 5.59 to 12.48, representing a 123.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Liaoning Chengda Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Liaoning Chengda Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Liaoning Chengda Biotechnology Co

All Key Metrics — Liaoning Chengda Biotechnology Co